PK modulation of haptenylated peptides via non-covalent antibody complexation

Journal of Controlled Release

Volumn 171, Issue 1, 2013, Pages 48-56

  Hoffmann, Eike ^a   Konkar, Anish ^b   Dziadek, Sebastian ^c   Josel, Hans Peter ^c   Conde Knape, Karin ^b   Kropp, Holger ^a   Kling, Lothar ^a   Stubenrauch, Kay ^a   Thorey, Irmgard ^a   Dengl, Stefan ^a   Brinkmann, Ulrich ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Diabetes; Digoxigenin; Pharmacokinetics; PYY

Indexed keywords

AMINO ACIDS; ANTIBODIES; BINS; MEDICAL PROBLEMS; MODULATION; PHARMACOKINETICS;

ANTIBODY COMPLEXES; DIET-INDUCED OBESITY; DIGOXIGENIN; NON-COVALENT COMPLEXES; PHARMACOKINETIC PROPERTIES; PROLONGED SERUM HALF-LIFE; THERAPEUTIC EFFICACY; THERAPEUTIC PEPTIDES;

PEPTIDES;

DIGOXIGENIN; PEPTIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMPLEXATION; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

CARBOXYMETHYL ETHER; CME; DIABETES; DIG; DIGOXIGENIN; H-CHAIN; HEAVY CHAIN; L-CHAIN; LIGHT CHAIN; PHARMACOKINETICS; PYY; SEC; SIZE EXCLUSION CHROMATOGRAPHY; SPR; SURFACE PLASMON RESONANCE;

ANIMALS; DIET, HIGH-FAT; DIGOXIGENIN; EATING; FEMALE; HAPTENS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; OBESITY; PEPTIDES; PURINERGIC P2Y RECEPTOR AGONISTS; RECEPTORS, PURINERGIC P2Y;

EID: 84885099398     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.06.021     Document Type: Article

References (30)

1. S. Syed, P.D. Schuyler, M. Kulczycky, W.P. Sheffield, Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin, Blood 89 (1997) 3243-3252. (Pubitemid 27229809)
2. V.M. Ahrens, K. Bellmann-Sickert, A.G. Beck-Sickinger, Peptides and peptide conjugates: therapeutics on the upward path, Future Med. Chem 4 (12) (Aug 4 2012) 1567-1586.
3. M.S. Dennis, M. Zhang, Y.G. Meng, M. Kadkhodayan, D. Kirchhofer, D. Combs, LA. Damico, Albumin binding as a general strategy for improving the pharmacokinetics of proteins, J. Biol. Chem 277 (2002) 35035-35043.
4. M. Hutt, A. Färber-Schwarz, F. Unverdorben, F. Richter, R.E. Kontermann, Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains, J. Biol. Chem 287 (2012) 4462-4469.
5. R.E. Kontermann, Strategies for extended serum half-life of protein therapeutics, Curr. Opin. Biotechnol. 22 (2011) 868-876.
6. X.J. Chu, D. Bartkovitz, W. Danho, J. Swistok, A.W. Cheung, G. Kurylko, K. Rowan, M. Yeon, L Franco, L Qi, L Chen, K. Yagaloff, Discovery of 1-amino-4-phenylcyclohexane-1-carboxylic acid and its influence on agonist selectivity between human melanocortin-4 and-1 receptors in linear pentapeptides, Bioorg. Med. Chem. Lett. 15 (2005) 4910-4914. (Pubitemid 41400154)
7. W. Danho, J. Swistok, W. Khan, X.J. Chu, A. Cheung, D. Fry, H. Sun, G. Kurylko, L Rumennik, J. Cefalu, G. Cefalu, P. Nunn, Opportunities and challenges of developing peptide drugs in the pharmaceutical industry, Adv. Exp. Med. Biol. 611 (2009) 467-469.
8. J. González-Valdez, M. Rito-Palomares, J. Benavides, Advances and trends in the design, analysis, and characterization of polymer-protein conjugates for "PEGylaided," bioprocesses, Anal. Bioanal. Chem. 403 (2012) 2225-2235.
9. G. Pasut, F.M. Veronese, State of the art in PEGylation: the great versatility achieved after forty years of research, J. Control. Release 161 (2012) 461-472.
10. M. Grant, A. Leone-Bay, Peptide therapeutics: it's all in the delivery, Ther. Deliv. 3 (2012) 981-996.
11. M. Antonelli, C. Sandroni, Hydroxy ethyl starch for intravenous volume replacement: more harm than benefit, JAMA 309 (2013) 723-724.
12. V.R. Doppalapudi, N. Tryder, L. Li, T. Aja, D. Griffith, F.F. Liao, G. Roxas, M.P. Ramprasad, C. Bradshaw, CF. Barbas, Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies, Bioorg. Med. Chem. Lett 17 (2007) 501-506. (Pubitemid 46073729)
13. M.S. Palanki, A. Bhat, B. Bolanos, F. Brunel, J. Del Rosario, D. Dettling, M. Horn, R. Lappe, R. Preston, A. Sievers, N. Stankovic, G. Woodnut, G. Chen, Development of a long acting human growth hormone analog suitable for once a week dosing, Bioorg. Med. Chem. Lett. 23 (2013) 402-406.
14. H.J. Holtke, W. Ankenbauer, K. Mühlegger, R. Rein, G. Sagner, R. Seibl, T. Walter, The digoxigenin (DIG) system for non-radioactive labelling and detection of nucleic acids - An overview, Cell. Mol. Biol. 41 (1995) 883-905.
15. C. Kessler, The digoxigenin:anti-digoxigenin (DIG) technology - A survey on the concept and realization of a novel bioanalytical indicator system, Mol. Cell. Probes 5 (1991) 161-205.
16. S. Metz, A.K. Haas, K. Daub, R. Croasdale, J. Stracke, W. Lau, G. Georges, H.P. Josel, S. Dziadek, K.P. Hopfner, A. Lammens, W. Scheuer, E. Hoffmann, O. Mundigl, U. Brinkmann, Bispecific digoxigenin-binding antibodies for targeted payload delivery, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 8194-8199.
17. U. Brinkmann, S. Dziadek, E. Hoffmann, A Pharmaceutical Composition of a Complex of an Anti-dig Antibody and Digoxigenin that is Conjugated to a Peptide, WO/2012/093068, 2012.
18. K. Conde-Knape, W. Danho, G. Ehrlich, N. Fotouhi, D.C. Fry, W. Khan, A. Konkar, C.M. Rondinone, J. Swistok, R.A. Taub, J.W. Tilley, Neuropeptide-2 Receptor Agonists WO/2007/065808, 2007.
19. K. Simpson, J. Parker, J. Plumer, S. Bloom, CCK, PYY and PP: the control of energy balance, Handb. Exp. Pharmacol. 209 (2012) 209-230.
20. F.M. Dautzenberg, S. Neysari, Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors, Pharmacology 75 (2005) 21-29. (Pubitemid 41491320)
21. A.D. Nguyen, H. Herzog, A. Sainsbury, Neuropeptide Y and peptide YY: important regulators of energy metabolism, Curr. Opin. Endocrinol. Diabetes Obes. 18 (2011) 56-60.
22. S. Zac-Varghese, A. De Silva, S.R. Bloom, Translational studies on PYY as a novel target in obesity, Curr. Opin. Pharmacol. 11 (2011) 582-585.
23. W.D. Bradley, C. Zwingelstein, C.M. Rondinone, The emerging role of the intestine in metabolic diseases, Arch. Physiol. Biochem. 117 (2011) 165-176.
24. E. Sebokova, A. Bénardeau, U. Sprecher, S. Sewing, L. Tobalina, C. Migliorini, Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat, Diabetes Obes. Metab. 8 (2010) 674-682.
25. F. Unverdorben, A. Färber-Schwarz, F. Richter, M. Hutt, R.E. Kontermann, Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A, Protein Eng. Des. Sel. 25 (2012) 81-88.
26. J. Hopp, N. Hornig, K.A. Zettlitz, A. Schwarz, N. Fuss, D. Müller, R.E. Kontermann, The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein, Protein Eng. Des. Sel. 23 (2010) 827-834.
27. D. Müller, A. Karle, B. Meissburger, I. Höfig, R. Stork, R.E. Kontermann, Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin, J. Biol. Chem. 282 (2007) 12650-12660. (Pubitemid 47100581)
28. H. Thie, B. Voedisch, S. Dübel, M. Hust, T. Schirrmann, Affinity maturation by phage display, Methods Mol. Biol. 525 (2009) 309-322.
29. S.J. Soldin, Digoxin - issues and controversies, Clin. Chem. 32 (1986) 5-12. (Pubitemid 17033767)
30. F. Lapostolle, S.W. Borron, C. Verdier, P. Taboulet, G. Guerrier, F. Adnet, J.L. Clemessy, C. Bismuth, F.J. Baud, Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning, Crit. Care Med. 36 (2008) 3014-3018.